Deutsch | English | по-русски | Türkçe 

Publikationen 2017

78.

Zenz T, Kreuz M, Fuge M, Klapper W, Horn H, Staiger AM, Winter D, Helfrich H, Huellein J, Hansmann ML, Stein H, Feller A, Möller P, Schmitz N, Trümper L, Loeffler M, Siebert R, Rosenwald A, Ott G, Pfreundschuh M, Stilgenbauer S; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

TP53 mutation and survival in aggressive B cell lymphoma.

Int J Cancer. 2017 Jun 14. [Epub ahead of print]

77.

Schuler PJ, Laban S, Doescher J, Bullinger L, Hoffmann TK.

Novel Treatment Options in Head and Neck Cancer.

Oncol Res Treat. 2017 May 17;40(6). [Epub ahead of print]

76.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JCY, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

J Clin Invest. 2017 May 8. [Epub ahead of print].

75.

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee..

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Ann Oncol. 2017 Apr 27. [Epub ahead of print]. No abstract available.

74.

Knop S, Langer C, Engelhardt M, Mügge LO, Reichle A, Rösler W, Bassermann F, Hertenstein B, Kunitz A, Röllig C, Ostermann H, Schäfer-Eckart K, Ringhoffer M, Günther A, Junghanss C, Biersack H, Schreder M, Liebert A, Held S, Einsele H, Bargou RC.

Lenalidomide, adriamycin, dexamethasone (RAD) for induction followed by stem-cell transplant in newly diagnosed myeloma.

Leukemia. 2017 Apr 25.  [Epub ahead of print].

73.

Thiel VN, Giaimo BD, Schwarz P, Soller K, Vas V, Bartkuhn M, Blätte TJ, Döhner K, Bullinger L, Borggrefe T, Geiger H, Oswald F.

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.

Leukemia. 2017 Apr 25. [Epub ahead of print].

72.

Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C.

Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.

Leukemia. 2017 Apr 18. [Epub ahead of print]

71.

Reichenbach F, Wiedenmann C, Schalk E, Becker D, Funk K, Scholz-Kreisel P, Todt F, Wolleschak D, Dohner K, Marquardt JU, Heidel F, Edlich F.

Mitochondrial BAX determines the predisposition to apoptosis in human AML.

Clin Cancer Res. 2017 Apr 18.  [Epub ahead of print].

70.

Thomsen H, Campo C, Weinhold N, Filho MI, Pour L, Gregora E, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Goldschmidt H, Hemminki K, Försti A.

Genome-wide association study on monoclonal gammopathy of unknown significance (MGUS).

Eur J Haematol. 2017 Apr 4. [Epub ahead of print].

69.

Einsele H, Knop S, Vogel M, Müller J, Kropff M, Metzner B, Langer C, Sayer H, Jung W, Dürk HA, Salwender H, Wandt H, Bassermann F, Gramatzki M, Rösler W, Wolf HH, Brugger W, Engelhardt M, Fischer T, Liebisch P, Straka C.

Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma.

Leukemia. 2017 Mar 15. [Epub ahead of print].

68.

Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E; & the ESMO Lymphoma Consensus Conference Panel Members.

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.

Ann Oncol. 2017 Mar 27. [Epub ahead of print].

67.

Beck M, Mandal T, Buske C, Lindén M.

Serum protein adsorption enhances active leukemia stem cell targeting of mesoporous silica nanoparticles.

ACS Appl Mater Interfaces. 2017 May 19. [Epub ahead of print].

66.

Stöckelmaier L, Renovanz M, König J, Nickel K, Hickmann AK, Mayer-Steinacker R, Nadji-Ohl M, Ganslandt O, Bullinger L, Wirtz CR, Coburger J.

Therapy for recurrent high-grade gliomas: Results of a prospective multicenter study on health-related quality of life.

World Neurosurg. 2017 Mar 10. [Epub ahead of print].

65.

Nickel K, Renovanz M, König J, Stöckelmaier L, Hickmann AK, Nadji-Ohl M, Engelke J, Weimann E, Freudenstein D, Ganslandt O, Bullinger L, Wirtz CR, Coburger J.

The patients' view: impact of the extent of resection, intraoperative imaging, and awake surgery on health-related quality of life in high-grade glioma patients-results of a multicenter cross-sectional study.

Neurosurg Rev. 2017 Mar 6. [Epub ahead of print].

64.

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.

Leukemia. 2017 Feb 17. [Epub ahead of print]

63.

Liu X, Pichulik T, Wolz O, Dang TM, Stutz A, Dillen C, Delmiro Garcia M, Kraus H, Dickhöfer S, Daiber E, Münzenmayer L, Wahl S, Rieber N, Kümmerle-Deschner J, Yazdi A, Franz-Wachtel M, Macek B, Radsak M, Vogel S, Schulte B, Walz JS, Hartl D, Latz E, Stilgenbauer S, Grimbacher B, Miller L, Brunner C, Wolz C, Weber AN.

Human NLRP3 inflammasome activity is regulated by and potentially targetable via BTK.

J Allergy Clin Immunol. 2017 Feb 16. [Epub ahead of print].

62.

Rohde M, Bonn BR, Zimmermann M, Lange J, Möricke A, Klapper W, Oschlies I, Szczepanowski M, Nagel I, Schrappe M, Loeffler M, Siebert R, Reiter A, Burkhardt B; ICGC-MMML-Seq; MMML-MYC-SYS.

Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the NHL-BFM protocols.

Haematologica. 2017 Feb 16. [Epub ahead of print].

61.

Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Leukemia. 2017 Jan 19. [Epub ahead of print].

60.

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT.

Leukemia. 2017 Jan 16. [Epub ahead of print].

59.

Roberts AW, Stilgenbauer S, Seymour JF, Huang DC.

Venetoclax in patients with previously treated chronic lymphocytic leukemia.

Clin Cancer Res. 2017 Jan 18. [Epub ahead of print].

58.

Krönke J, Kuchenbauer F, Kull M, Teleanu V, Bullinger L, Bunjes D, Greiner A, Kolmus S, Köpff S, Schreder M, Mügge LO, Straka C, Engelhardt M, Döhner H, Einsele H, Bassermann F, Bargou R, Knop S, Langer C.

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).

Leukemia. 2016 Dec 26. [Epub ahead of print].

57.

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichman M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk R, Döhner K, Döhner H, Ganser A, Heuser M.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Leukemia. 2016 Nov 24. [Epub ahead of print].

56.

Pankrath AL, Weißflog G, Mehnert A, Niederwieser D, Döhner H, Hönig K, Gündel H, Vogelhuber M, Friedrich M, Ernst J.

The relation between dyadic coping and relationship satisfaction in couples dealing with haematological cancer.

Eur J Cancer Care (Engl). 2016 Oct 24. [Epub ahead of print].

55.

Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S.

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

J Clin Oncol. 2016 Aug 29. [Epub ahead of print].

54.

Scheffold A, Jebaraj BM, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S.

Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.

Br J Haematol. 2016 Jul 8. [Epub ahead of print]. No abstract available.

53.

Went M, Sud A, Law PJ, Johnson DC, Weinhold N, Försti A, van Duin M, Mitchell JS, Chen B, Kuiper R, Stephens OW, Bertsch U, Campo C, Einsele H, Gregory WM, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Langer C, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Hemminki K, Nilsson B, Morgan GJ, Houlston RS.

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.

Blood Cancer J. 2017 Jun 16;7(6):e573.

52.

Edenhofer SA, Stilgenbauer S.

Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges.

J Oncol Pract. 2017 Jun;13(6):381-382.

51.

Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D.

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.

Ann Hematol. 2017 Jun;96(6):887-894. Epub 2017 Apr 3.

50.

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Blood Cancer J. 2017 May 26;7(5):e564.

49.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek D, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K.

CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED IGHV4-34 RECEPTORS: SHARED AND DISTINCT IMMUNOGENETIC FEATURES AND CLINICAL OUTCOMES.

Clin Cancer Res. 2017 May 23. [Epub ahead of print]

48.

Jäger D, Barth TFE, Brüderlein S, Scheuerle A, Rinner B, von Witzleben A, Lechel A, Meyer P, Mayer-Steinacker R, Baer AV, Schultheiss M, Wirtz CR, Möller P, Mellert K.

HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.

Sci Rep. 2017 May 17;7(1):2032.

47.

Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJ, Boettcher S, Ritgen M, Goede V, Mobasher M, Hallek M.

Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Blood.  2017 May 11;129(19):2702-2705.

46.

Lal R, Lind K, Heitzer E, Ulz P, Aubell K, Kashofer K, Middeke JM, Thiede C, Schulz E, Rosenberger A, Hofer S, Feilhauer B, Rinner B, Svendova V, Schimek MG, Rücker FG, Hoefler G, Döhner K, Zebisch A, Wölfler A, Sill H.

Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.

Blood. 2017 May 4;129(18):2587-2591.

45.

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; and for the German-Austrian AMLSG.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Leukemia. 2017 May;31(5):1217-1220.

44.

Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M.

Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.

Leukemia. 2017 May;31(5):1177-1186.

43.

Buske C, Ogura M, Kwon HC, Yoon SW.

An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.

Future Oncol. 2017 May;13(15s):5-16.

42.

Weißflog G, Hönig K, Gündel H, Lang D, Niederwieser D, Döhner H, Vogelhuber M, Mehnert A, Ernst J.

Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners.

Support Care Cancer. 2017 May;25(5):1445-1454. 2016 Dec 16.

41.

Schmitt M, Schmitt A, Wiesneth M, Hückelhoven A, Wu Z, Kuball J, Wang L, Schauwecker P, Hofmann S, Götz M, Michels B, Maccari B, Wuchter P, Eckstein V, Mertens T, Schnitzler P, Döhner H, Ho AD, Bunjes DW, Dreger P, Schrezenmeier H, Greiner J.

Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.

Theranostics. 2017 Apr 10;7(6):1705-1718. eCollection 2017.

 

40.

Kassubek R, Bullinger L, Kassubek J, Dreyhaupt J, Ludolph AC, Althaus K, Lewerenz J.

Identifying ischemic stroke associated with cancer: a multiple model derived from a case-control analysis.

J Neurol. 2017 Apr;264(4):781-791.

39.

Schlenk RF*, Stegelmann F*, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K, *equal contribution.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Leukemia.2017 Apr;31(4):889-895.

38.

Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P.

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG).

Leukemia. 2017 Apr;31(4):1012-1015.

37.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Lancet Oncol. 2017 Apr;18(4):454-463. Epub 2017 Feb 22.

36.

Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK.

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Haematologica. 2017 Apr;102(4):e156-e159. 2016 Dec 15. No abstract available.

35.

Hillenbrand A, Gruener B, Kratzer W, Kern P, Graeter T, Barth TF, Buttenschoen K, Henne-Bruns D.

Impact of Safe Distance on Long-Term Outcome After Surgical Therapy of Alveolar Echinococcosis.

World J Surg. 2017 Apr;41(4):1012-1018.

34.

Gökbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A, Horst HA, Neumann S, Brüggemann M, Ottmann OG, Burmeister T, Wessiepe D, Topp MS, Bargou R.

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.

Haematologica. 2017 Apr;102(4):e132-e135. No abstract available.

33.

Fürst D, Niederwieser D, Bunjes D, Wagner EM, Gramatzki M, Wulf G, Müller CR, Neuchel C, Tsamadou C, Schrezenmeier H, Mytilineos J.

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.

Haematologica. 2017 Apr;102(4):796-803.

32.

Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.

Ann Hematol. 2017 Apr;96(4):559-565.

31.

Khadivjam B, Stegen C, Hogue-Racine MA, El Bilali N, Döhner K, Sodeik B, Lippé R.

The ATP-Dependent RNA Helicase DDX3X Modulates Herpes Simplex Virus 1 Gene Expression.

J Virol. 2017 Mar 29;91(8).

30.

Bullinger L, Döhner K, Döhner H.

Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.

J Clin Oncol. 2017 Mar 20;35(9):934-946. Epub 2017 Feb 13.

29.

Mertens D, Stilgenbauer S.

Ibrutinib-resistant CLL: unwanted and unwonted!

Blood. 2017 Mar 16;129(11):1407-1409. No abstract available.

28.

Tasdogan A, Kumar S, Allies G, Bausinger J, Beckel F, Hofemeister H, Mulaw M, Madan V, Scharffetter-Kochanek K, Feuring-Buske M, Doehner K, Speit G, Stewart AF, Fehling HJ.

DNA Damage-Induced HSPC Malfunction Depends on ROS Accumulation Downstream of IFN-1 Signaling and Bid Mobilization.

Cell Stem Cell. 2017 Mar 2;20(3):415. No abstract available.

27.

van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2017 Mar;52(3):372-380. 2016 Dec 12.

26.

Gerstung M,* Papaemmanuil E,* Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H,* Campbell PJ.*

Precision oncology for acute myeloid leukemia using a knowledge bank approach.

Nat Genet. 2017 Mar;49(3):332-340. 2017 Jan 16.  *Equal contribution

26.

Schwameis M, Kündig T, Huber G, von Bidder L, Meinel L, Weisser R, Aberer E, Härter G, Weinke T, Jelinek T, Fätkenheuer G, Wollina U, Burchard GD, Aschoff R, Nischik R, Sattler G, Popp G, Lotte W, Wiechert D, Eder G, Maus O, Staubach-Renz P, Gräfe A, Geigenberger V, Naudts I, Sebastian M, Reider N, Weber R, Heckmann M, Reisinger EC, Klein G, Wantzen J, Jilma B.

Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial.

Lancet Infect Dis. 2017 Mar;17(3):322-329.

25.

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P.

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet Oncol. 2017 Mar;18(3):297-311.

24.

Bogen A, Buske C, Hiddemann W, Bohlander SK, Christ O.

Variable aldehyde dehydrogenase activity and effects on chemosensitivity of primitive human leukemic cells.

Exp Hematol. 2017 Mar;47:54-63.

23.

Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM.

Alemtuzumab consolidation in chronic lymphocytic leukaemia: A phase I/II multicentre trial.

Eur J Haematol. 2017 Mar;98(3):254-262.

22.

Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S.

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.

Leukemia. 2017 Mar;31(3):734-738.

21.

Kern P, Menezes da Silva A, Akhan O, Müllhaupt B, Vizcaychipi KA, Budke C, Vuitton DA.

The Echinococcoses: Diagnosis, Clinical Management and Burden of Disease.

Adv Parasitol. 2017;96:259-369.Epub 2017 Feb 8.

20.

Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M.

Mutational landscape reflects the biological continuum of plasma cell dyscrasias.

Blood Cancer J. 2017 Feb 24;7(2):e537.

19.

Bohl SR, Dolnik A, Jensen T, Lang KM, Hackanson B, Gaidzik VI, Paschka P, Knudsen S, Döhner K, Döhner H, Claus R, Lübbert M, Bullinger L.

Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes.

Leuk Lymphoma. 2017 Feb 13:1-4. No abstract available.

18.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia..

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Lancet Oncol. 2017 Feb;18(2):241-250. 2016 Dec 9.

17.

Qu Y, Siggens L, Cordeddu L, Gaidzik VI, Karlsson K, Bullinger L, Döhner K, Ekwall K, Lehmann S, Lennartsson A

Cancer specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.

Blood. 2017 Feb 16;129(7):e13-e25.

16.

Chakrabortty S, Agrawalla BK, Stumper A, Vegi NM, Fischer S, Reichardt C, Kögler M, Dietzek B, Feuring-Buske M, Buske C, Rau S, Weil T.

Mitochondria Targeted Protein-Ruthenium Photosensitizer for Efficient Photodynamic Applications.

J Am Chem Soc. 2017 Feb 15;139(6):2512-2519.

15.

Schönsteiner S*, Bauder Mißbach H, Benner A, Mack S, Hamel T, Orth M, Landwehrmeyer B, Süßmuth S, Geitner C, Mayer‑Steinacker R, Riester A, Prokein A, Erhardt E, Kunecki J, Eisenschink A, Rawer R, Döhner H, Kirchner R, Schlenk RF

A randomized exploratory phase 2 study in patients with chemotherapy‑related peripheral neuropathy evaluating whole‑body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises.

Exp Hematol Oncol. 2017 Feb 7;6:5. eCollection 2017.

14.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Int J Mol Sci. 2017 Feb 15;18(2).

13.

Huber H, Edenhofer S, Estenfelder S, Stilgenbauer S.

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia.

Onco Targets Ther. 2017 Feb 7;10:645-656. eCollection 2017.

12.

Eder S, Labopin M, Finke J, Bunjes D, Olivieri A, Santarone S, Rambaldi A, Kanz L, Messina G, Mohty M, Nagler A.

Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.

Bone Marrow Transplant. 2017 Feb;52(2):238-244.

11.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

J Clin Oncol. 2017 Feb 20;35(6):605-612.

10.

Robak T, Stilgenbauer S, Tedeschi A.

Front-line treatment of CLL in the era of novel agents.

Cancer Treat Rev. 2017 Feb;53:70-78. Review

9.

Dezsényi B, Strausz T, Makrai Z, Csomor J, Danka J, Kern P, Rezza G, Barth TF, Casulli A.

Autochthonous human alveolar echinococcosis in a Hungarian patient.

Infection. 2017 Feb;45(1):107-110.

8.

Rouhi A, Miller C, Grasedieck S, Reinhart S, Stolze B, Döhner H, Kuchenbauer F, Bullinger L, Fröhling S, Scholl C.

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.

Oncotarget. 2017 Jan 31;8(5):7678-7690.

7.

Kurth F, Develoux M, Mechain M, Malvy D, Clerinx J, Antinori S, Gjørup IE, Gascon J, Mørch K, Nicastri E, Ramharter M, Bartoloni A, Visser L, Rolling T, Zanger P, Calleri G, Salas-Coronas J, Nielsen H, Just-Nübling G, Neumayr A, Hachfeld A, Schmid ML, Antonini P, Lingscheid T, Kern P, Kapaun A, da Cunha JS, Pongratz P, Soriano-Arandes A, Schunk M, Suttorp N, Hatz C, Zoller T.

Severe malaria in Europe: an 8-year multi-centre observational study.

Malar J. 2017 Jan 31;16(1):57.

6.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Blood. 2017 Jan 26;129(4):424-447.

5.

Cusan M, Vegi NM, Mulaw MA, Bamezai S, Kaiser LM, Deshpande AJ, Greif PA, Quintanilla-Fend L, Göllner S, Müller-Tidow C, Humphries KR, Armstrong SA, Hiddemann W, Feuring-Buske M, Buske C.

Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus.

Blood. 2017 Jan 19;129(3):319-323.

4.

Neuchel C, Fürst D, Niederwieser D, Bunjes D, Tsamadou C, Wulf G, Pfreundschuh M, Wagner E, Stuhler G, Einsele H, Schrezenmeier H, Mytilineos J.

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study.

PLoS One. 2017 Jan 20;12(1):e0169512.

3.

Buske C.

Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?

Lancet Haematol. 2017 Jan;4(1):e4-e5.

2.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Associations between gender, disease features and symptom burden in the MPN population: An analysis by the MPN QOL International Working Group.

Haematologica. 2017 Jan;102(1):85-93.

1.

Hoffmann TK, Schuler PJ, Laban S, Grässlin R, Beer M, Beer AJ, Friebe-Hoffmann U, Bullinger L, Möller P, Wiegel T.

Response Evaluation in Head and Neck Oncology: Definition and Prediction.

ORL J Otorhinolaryngol Relat Spec. 2017;79(1-2):14-23.

gepunktete blaue Linie 1000px breit